UW Medicine Designs Precision Proteases for Targeted Protein Cleavage

Lab-tested synthetic enzymes could enable cheaper, more precise disease treatments by destroying specific proteins without systemic side effects.

UW Medicine Institute for Protein Design created synthetic proteases through computational design that cut target proteins at precisely specified sequences in lab tests. These enzymes were verified across multiple experimental settings and tested on purified proteins from Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The enzymes also functioned in human cell cultures in one study. Unlike traditional binding agents—which require one-to-one engagement with disease targets, needing millions of drug molecules per site—the designed proteases can cleave thousands to millions of target proteins per enzyme molecule. This precision enables targeted destruction of viral proteins, bacterial toxins, misfolded neurodegenerative proteins, and tissue-specific drug activation.

The breakthrough lies in the computational approach: the proteases are engineered to act at specific genetic sequences, avoiding the systemic effects of conventional drugs. This mechanism could drastically reduce treatment costs and side effects for conditions where protein misfolding drives disease.

If clinical efficacy follows the lab results, this approach could make targeted therapies significantly cheaper and more accessible—especially for neurodegenerative diseases where current treatments are expensive and imprecise. However, the current stage is strictly laboratory-based.

What to watch: In vivo efficacy beyond the single human cell study, and whether the precision translates to real-world clinical outcomes. Caveats: Lab tests only; clinical efficacy not established. The source describes in vivo testing as 'one study' in its reporting.

Source: HumanProgress